New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVesilute vs P21

Vesilute vs P21

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Vesilute
Cognitive EnhancementAnti-Aging & Longevity
P21
Summary
Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
P21 is a synthetic peptide derived from CNTF (ciliary neurotrophic factor) that promotes hippocampal neurogenesis, enhances memory and spatial learning, and may reduce amyloid-beta pathology. It is used as a neurogenic and cognitive enhancer with potential anti-Alzheimer's applications.
Half-Life
Short (minutes); sustained gene-regulatory effects
Not well characterized; likely short, but neurogenic effects persist long after administration
Admin Route
SubQ, Oral
SubQ, Intranasal
Research
Typical Dose
10 mg per day
100–500 mcg
Frequency
Daily for 10–30 days
Once daily
Key Benefits
  • Supports retinal photoreceptor cell function and survival
  • May slow progression of age-related macular degeneration
  • Reduces retinal cell apoptosis from oxidative stress and aging
  • Anti-aging effects on retinal pigment epithelium
  • Potential support in diabetic retinopathy management
  • Preserves visual acuity with aging
  • Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
  • Promotes hippocampal neurogenesis
  • Enhances spatial memory and learning
  • Increases BDNF expression
  • Reduces amyloid-beta plaque formation (animal models)
  • Anti-tau pathology potential
  • Cognitive enhancement without stimulant effects
  • Potential therapeutic for Alzheimer's and cognitive aging
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant ocular adverse events reported at standard doses
  • Generally well tolerated in animal studies
  • Limited human clinical data
  • Injection site reactions
  • Potential mild fatigue at initiation
Stacks With